Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma.
Cholangiocarcinoma has a poor prognosis and is refractory to conventional chemotherapy and radiation therapy. Improving survival of patients with advanced cholangiocarcinoma urgently requires the development of new effective targeted therapies in combination with chemotherapy. We previously develope...
Main Authors: | Seulki Cho, Tae Sup Lee, In Ho Song, A-Ram Kim, Yoon-Jin Lee, Haejung Kim, Haein Hwang, Mun Sik Jeong, Seung Goo Kang, Hyo Jeong Hong |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5293259?pdf=render |
Similar Items
-
High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin
by: Gunn Huh, et al.
Published: (2020-09-01) -
Radical resection of an initially unresectable intrahepatic cholangiocarcinoma after chemotherapy with using gemcitabine, cisplatin, and S-1: report of a case
by: Masashi Tsunematsu, et al.
Published: (2019-06-01) -
Successful radical surgical resection of initially unresectable intrahepatic cholangiocarcinoma by downsizing chemotherapy with gemcitabine plus cisplatin: a case report
by: Ryosuke Takayanagi, et al.
Published: (2017-11-01) -
Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine
by: Chiara Varamo, et al.
Published: (2019-04-01) -
Intrahepatic Cholangiocarcinoma Associated with Intrahepatic Duct Stones
by: Hoon Hur, et al.
Published: (2009-01-01)